SI9500220B - Vodne formulacije risperidona - Google Patents
Vodne formulacije risperidona Download PDFInfo
- Publication number
- SI9500220B SI9500220B SI9500220A SI9500220A SI9500220B SI 9500220 B SI9500220 B SI 9500220B SI 9500220 A SI9500220 A SI 9500220A SI 9500220 A SI9500220 A SI 9500220A SI 9500220 B SI9500220 B SI 9500220B
- Authority
- SI
- Slovenia
- Prior art keywords
- solution
- solution according
- range
- water
- risperidone
- Prior art date
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract 7
- 229960001534 risperidone Drugs 0.000 title claims abstract 7
- 239000000203 mixture Substances 0.000 title claims abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract 4
- 238000007911 parenteral administration Methods 0.000 claims abstract 3
- 239000007864 aqueous solution Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- 239000011975 tartaric acid Substances 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 239000003182 parenteral nutrition solution Substances 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/272,462 US5453425A (en) | 1994-07-11 | 1994-07-11 | Risperidone oral formulation |
| US08/429,435 US5616587A (en) | 1994-07-11 | 1995-04-26 | Aqueous risperidone formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9500220A SI9500220A (en) | 1996-02-29 |
| SI9500220B true SI9500220B (sl) | 2004-12-31 |
Family
ID=26955530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9500220A SI9500220B (sl) | 1994-07-11 | 1995-07-10 | Vodne formulacije risperidona |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US5453425A (et) |
| EP (1) | EP0769965B1 (et) |
| JP (1) | JP2872412B2 (et) |
| KR (1) | KR100212942B1 (et) |
| CN (1) | CN1148226C (et) |
| AP (1) | AP774A (et) |
| AT (1) | ATE206931T1 (et) |
| AU (1) | AU684193B2 (et) |
| BG (1) | BG63070B1 (et) |
| BR (1) | BR9508253A (et) |
| CA (1) | CA2194564C (et) |
| CY (1) | CY2268B1 (et) |
| CZ (1) | CZ285204B6 (et) |
| DE (1) | DE69523313T2 (et) |
| DK (1) | DK0769965T3 (et) |
| EE (1) | EE03426B1 (et) |
| ES (1) | ES2165918T3 (et) |
| FI (1) | FI116510B (et) |
| HR (1) | HRP950397B1 (et) |
| HU (1) | HU222352B1 (et) |
| IL (1) | IL114525A (et) |
| MX (1) | MX9700374A (et) |
| MY (1) | MY114389A (et) |
| NO (1) | NO320366B1 (et) |
| NZ (1) | NZ289432A (et) |
| PH (1) | PH31626A (et) |
| PL (1) | PL179972B1 (et) |
| PT (1) | PT769965E (et) |
| RO (1) | RO116778B1 (et) |
| RU (1) | RU2161965C2 (et) |
| SI (1) | SI9500220B (et) |
| SK (1) | SK282159B6 (et) |
| TR (1) | TR199500778A1 (et) |
| TW (1) | TW420615B (et) |
| WO (1) | WO1996001652A1 (et) |
| ZA (1) | ZA955720B (et) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG47445A1 (en) | 1993-11-19 | 1998-04-17 | Janssen Pharmaceutica Nv | Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles |
| US5453425A (en) * | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US6682758B1 (en) | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| SE0103211D0 (sv) * | 2001-09-27 | 2001-09-27 | Pharmacia Ab | New formulations and use thereof |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| WO2004017975A1 (en) * | 2002-08-23 | 2004-03-04 | Ranbaxy Laboratories Limited | Stable aqueous solutions of risperidone and methods for their preparation |
| EP1615923A1 (en) * | 2003-04-22 | 2006-01-18 | Synthon B.V. | Risperidone monohydrochloride |
| AR044852A1 (es) | 2003-06-24 | 2005-10-05 | Novartis Ag | Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina |
| US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
| ES2245252B1 (es) * | 2004-06-15 | 2007-03-01 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
| ES2245891B1 (es) * | 2004-07-09 | 2006-11-16 | Clinmet S.L. | "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo". |
| WO2006129160A2 (en) * | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
| ES2323286T3 (es) * | 2005-06-29 | 2009-07-10 | Verisfield (Uk) Ltd. | Composiciones farmaceuticas de risperidona en disolucion acuosa. |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| JP4922657B2 (ja) * | 2006-05-09 | 2012-04-25 | 高田製薬株式会社 | リスペリドン経口用液剤 |
| WO2007138462A2 (en) * | 2006-06-01 | 2007-12-06 | Wockhardt Ltd | Aqueous oral formulations of risperidone |
| WO2008153611A2 (en) | 2007-05-25 | 2008-12-18 | Qlt Usa, Inc. | Sustained delivery formulations of risperidone compounds |
| US7776866B2 (en) * | 2007-09-15 | 2010-08-17 | Protia, Llc | Deuterium-enriched risperidone |
| AU2008340101C1 (en) * | 2007-12-19 | 2025-03-06 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
| WO2010085452A1 (en) * | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| EP3718547A1 (en) * | 2011-10-03 | 2020-10-07 | The University of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CA3015557C (en) | 2014-11-07 | 2019-07-16 | Indivior Uk Limited | The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders |
| CA3027300C (en) | 2016-06-13 | 2023-08-08 | Syneurx International (Taiwan) Corp. | Co-crystals of lithium benzoate and uses thereof |
| JP6958922B2 (ja) | 2016-06-13 | 2021-11-02 | シニュークス インターナショナル(タイワン)コーポレイション | 安息香酸ナトリウムの共結晶及びその使用 |
| KR102728012B1 (ko) * | 2016-09-23 | 2024-11-11 | 델포어, 인코포레이티드 | 소분자 치료제 화합물 조성물 |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| RU2646812C1 (ru) * | 2016-10-24 | 2018-03-07 | Общество с ограниченной ответственностью "Трейдсервис" | Жидкая лекарственная форма рисперидона и способ ее получения |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| CN107260662A (zh) * | 2017-06-21 | 2017-10-20 | 南京正科医药股份有限公司 | 一种利培酮口服溶液及其制备方法 |
| CN107441037A (zh) * | 2017-08-16 | 2017-12-08 | 南京正科医药股份有限公司 | 一种利培酮口服溶液 |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| EP3758701A1 (en) * | 2018-02-27 | 2021-01-06 | Delpor, Inc. | Compositions for small molecule therapeutic agent compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337261A (en) * | 1980-07-28 | 1982-06-29 | Hoechst-Roussel Pharmaceuticals Inc. | (1,2-Benzisoxazol)phenoxyacetic acids as diuretics |
| US4793992A (en) * | 1987-03-25 | 1988-12-27 | Redken Laboratories, Inc. | Hair treatment composition |
| IL88233A (en) * | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
| FR2641278B1 (fr) * | 1989-01-05 | 1991-03-22 | Lipha | Piperidines, procedes de preparation et medicaments les contenant |
| DK203990D0 (da) * | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| US5453425A (en) * | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| FR2796273B1 (fr) * | 1999-07-15 | 2003-09-12 | Oreal | Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux |
-
1994
- 1994-07-11 US US08/272,462 patent/US5453425A/en not_active Expired - Lifetime
-
1995
- 1995-04-26 US US08/429,435 patent/US5616587A/en not_active Ceased
- 1995-05-19 TW TW084104959A patent/TW420615B/zh not_active IP Right Cessation
- 1995-05-31 PH PH50624A patent/PH31626A/en unknown
- 1995-06-29 TR TR95/00778A patent/TR199500778A1/xx unknown
- 1995-07-04 JP JP8504108A patent/JP2872412B2/ja not_active Expired - Lifetime
- 1995-07-04 AU AU29275/95A patent/AU684193B2/en not_active Expired
- 1995-07-04 NZ NZ289432A patent/NZ289432A/en not_active IP Right Cessation
- 1995-07-04 EE EE9700009A patent/EE03426B1/et unknown
- 1995-07-04 CZ CZ9727A patent/CZ285204B6/cs not_active IP Right Cessation
- 1995-07-04 SK SK22-97A patent/SK282159B6/sk not_active IP Right Cessation
- 1995-07-04 AP APAP/P/1997/000910A patent/AP774A/en active
- 1995-07-04 CN CNB951940821A patent/CN1148226C/zh not_active Expired - Lifetime
- 1995-07-04 BR BR9508253A patent/BR9508253A/pt not_active IP Right Cessation
- 1995-07-04 RO RO97-00032A patent/RO116778B1/ro unknown
- 1995-07-04 AT AT95924978T patent/ATE206931T1/de active
- 1995-07-04 MX MX9700374A patent/MX9700374A/es unknown
- 1995-07-04 EP EP95924978A patent/EP0769965B1/en not_active Expired - Lifetime
- 1995-07-04 KR KR1019970700039A patent/KR100212942B1/ko not_active Expired - Lifetime
- 1995-07-04 WO PCT/EP1995/002615 patent/WO1996001652A1/en not_active Ceased
- 1995-07-04 ES ES95924978T patent/ES2165918T3/es not_active Expired - Lifetime
- 1995-07-04 PT PT95924978T patent/PT769965E/pt unknown
- 1995-07-04 CA CA002194564A patent/CA2194564C/en not_active Expired - Lifetime
- 1995-07-04 DE DE69523313T patent/DE69523313T2/de not_active Expired - Lifetime
- 1995-07-04 PL PL95318132A patent/PL179972B1/pl unknown
- 1995-07-04 HU HU9700082A patent/HU222352B1/hu active IP Right Grant
- 1995-07-04 RU RU97102139/14A patent/RU2161965C2/ru active
- 1995-07-04 DK DK95924978T patent/DK0769965T3/da active
- 1995-07-10 SI SI9500220A patent/SI9500220B/sl active Search and Examination
- 1995-07-10 IL IL11452595A patent/IL114525A/xx not_active IP Right Cessation
- 1995-07-10 HR HR950397A patent/HRP950397B1/xx not_active IP Right Cessation
- 1995-07-10 ZA ZA955720A patent/ZA955720B/xx unknown
- 1995-07-11 MY MYPI95001944A patent/MY114389A/en unknown
-
1997
- 1997-01-04 BG BG101106A patent/BG63070B1/bg unknown
- 1997-01-07 NO NO19970051A patent/NO320366B1/no not_active IP Right Cessation
- 1997-01-10 FI FI970109A patent/FI116510B/fi not_active IP Right Cessation
-
2001
- 2001-12-04 US US09/955,274 patent/USRE39181E1/en not_active Expired - Lifetime
-
2002
- 2002-04-25 CY CY0200019A patent/CY2268B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9500220B (sl) | Vodne formulacije risperidona | |
| US5024997A (en) | Palatable ibuprofen solutions | |
| ES2215223T3 (es) | Suspensiones liquidas de sabor enmascarado. | |
| CA1320192C (en) | Pharmaceutical compositions | |
| RU97102139A (ru) | Водные композиции рисперидона | |
| CA2478411C (en) | Palatable oral suspension and method | |
| AU706027B2 (en) | Pharmaceutical composition for oral administration of flavonoids | |
| TW349870B (en) | An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof | |
| ES2347536T3 (es) | Composiciones particuladas de axetil cefuroxima revestidas. | |
| PT92271B (pt) | Processo para a obtencao de preparacoes efervescentes de ibuprofeno | |
| ZA200201904B (en) | Topical suspension formulations containing ciprofloxacin and dexamethasone. | |
| RU96123917A (ru) | Пероральные жидкие композиции, содержащие алендронат | |
| CA2452638A1 (en) | Optimised formulation of tobramycin for aerosolization | |
| ES2235834T3 (es) | Matriz directamente comprimible para la liberacion controlada de dosis diarias unicas de claritromicina. | |
| CA2392050A1 (en) | Pharmaceutical formulations containing zolmitriptan | |
| ZA894828B (en) | Process for the preparation of anti-inflammatory pharmaceutical agents with an ibuprofen base,with elimination,in solution,of the bitter taste,burning of the throat and intestinal toxicity | |
| AU638484B2 (en) | Non-effervescent ibuprofen compositions | |
| CA2234426A1 (en) | Antibacterial composition for oral administration | |
| US5422102A (en) | Antiinflammatory and analgesic gel preparation | |
| US20040241235A1 (en) | Granules and granules coated with a masked taste | |
| DK175752B1 (da) | Flydende oralt farmaceutisk diclofenacpræparat og fremgangsmåde til fremstilling deraf | |
| SK100998A3 (en) | Pharmaceutical compositions of cilansetron stabilized against racemisation | |
| JPH0717863A (ja) | プラノプロフェン点眼液 | |
| US5696095A (en) | Pharmaceutical formulations of spiramycin | |
| JP4134358B2 (ja) | ビオチンの溶解方法及び内服液剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20041103 |
|
| IF | Valid on the event date |